And, BMI can help show need for extra breast cancer screening.

View in Browser

Sign up for Reuters newsletters

Reuters
Reuters
Reuters
Reuters

Health Rounds

By Nancy Lapid, Health Science Editor

Hello Health Rounds readers! The use of artificial intelligence in everyday life is likely to expand into informed consent discussions ahead of medical procedures, with a new report suggesting consent may be more efficiently obtained by chatbots than by humans. We also look at a study suggesting that body mass index (BMI) should be considered along with breast density when identifying patients who need extra tests to screen for breast cancer. Another study finds that U.S. adolescents with drug addiction issues often can't access the standard treatment.

 

In breaking news, see these stories from our Reuters journalists: BioNTech faces first German lawsuit over alleged COVID vaccine side effects; U.S. seeks new suppliers of highly used cancer drug methotrexate in short supply; European experts unconvinced new Alzheimer’s drug will be worth the expense; FDA advises drugmakers on updating COVID shots for 2023-24; childhood vaccination rates show signs of recovery after pandemic backslide; and Italy to pass 'right to be forgotten' law for cancer survivors.

 

Our industry news headlines report Novartis buys Chinook for $3.5 bln; Catalent shares jump; Illumina CEO resigns; BioNTech vaccine hearing postponed; Biogen shares rise; and AstraZeneca turns to cows to cut U.S. carbon footprint.

When screening mammograms show high levels of breast density, supplemental imaging studies are recommended, but a new report says factoring in body weight index would improve identification of patients who would benefit from the additional tests to rule out breast cancer. REUTERS/Jean-Paul Pelissier

Study Rounds

Chatbots may soon be requesting informed consent

In the future, it might be a chatbot that explains the risks of an upcoming medical procedure and asks you for informed consent instead of a human, researchers say.

 

They studied 35 families who completed the informed consent process for a genetics study using a chatbot and 37 families who completed the process the traditional way.

 

The bot, developed by Invitae Corp, could be accessed at any time, allowing those with less free time to use it outside normal business hours, the researchers said on Tuesday at the annual European Society of Human Genetics meeting in Glasgow, Scotland.

 

With the chatbot, the average duration of the consent conversation was 44 minutes, versus 76 minutes with a human, and the average time from first meeting with the researchers to completion of the consent process was five days versus 16 days.

 

Among those who used the bot, 96% were able to pass the bot's 10-question quiz, according to the researchers.

 

"The traditional method of consenting does not have a mechanism to verify understanding objectively," study leader Dr. Eric Vilain of the University of California, Irvine said in a statement. It is based on the conviction of the person conducting the conversation that the patient understands what they are consenting to, he added.

 

The chatbot tests comprehension objectively, Vilain said.  Users who do not show understanding are not allowed to give consent and instead are put in touch with a member of the research team.

 

Essential Reading on Reuters.com

  • Britain's COVID-19 inquiry hears government was under-prepared.
  • Macron plans to relocate production of key drugs to France.
  • New York City opens a public health vending machine.
 

Consider body mass index along with breast density for cancer risk

Along with breast density, body mass index (BMI) should be considered when identifying women who could benefit from supplemental imaging studies for breast cancer screening, researchers said.

 

Otherwise, the risks conferred by dense breast tissue are likely to be underestimated in Black women, and they are less likely to undergo additional testing, the researchers warn.

 

Black women with breast cancer have higher rates of more aggressive forms of the disease. Their breast cancers are also more often missed on mammograms and later diagnosed at advanced stages.

 

Dense breast tissue can mask a potential cancer and increase the chance it will go undetected on mammography. Radiologists determine a woman's level of breast density based on the ratio of nondense tissue to dense tissue on her mammogram. Slender women are more likely to have higher proportions of dense breast tissue.

 

In a study of more than 860,000 women published in Cancer Epidemiology, Biomarkers & Prevention, researchers found that Black women had the lowest prevalence of dense breasts but the highest prevalence of obesity, another risk factor for breast cancer.

 

Without consideration of body mass index, a given volume of dense breast tissue is less likely to trigger a breast density warning and less likely to lead to supplemental imaging in Black women, researchers found.

 

In many states, women must be notified if mammograms show high levels of breast density, but state laws do not consider other breast cancer risk factors, the researchers note.

 

"The goal of breast notification laws is to identify women who are at increased risk of breast cancer and might benefit from supplemental imaging," said study leader Dr. Karla Kerlikowske of the University of California, San Francisco.

 

"Incorporating breast density and BMI would better identify women with high breast density at risk of a missed or advanced cancer rather than using breast density alone," she said.

 

Read more about breast cancer screening on Reuters.com

  • US panel drops mammography screening age back to 40
  • FDA mandates breast density information with mammography results

 

U.S. kids with drug addiction don't get standard treatment

U.S. adolescents with serious substance abuse issues often miss out on evidence-based addiction treatment, a study found.

 

Only one-in-four residential addiction treatment facilities caring for U.S. adolescents under age 18 offer buprenorphine for treating opioid use disorder, and only one-in-eight offer it for ongoing treatment, researchers reported on Tuesday in JAMA.

 

"It is tragic to see that young people with opioid use disorder are unable to access buprenorphine in most treatment facilities, despite this medication being the standard of care for people aged 16 and older," said study coauthor Dr. Nora Volkow, director of the National Institute on Drug Abuse, in a statement

 

The researchers identified 160 residential treatment centers across the country that accepted adolescents under age 18 and called them by phone, posing as family members inquiring about services for a 16-year-old with a recent non-fatal fentanyl overdose.

 

Only 39 facilities (24%) said they offered buprenorphine to patients aged 16 or older, and 12 (7.5%) offered the medication to adolescents under age 16. Twenty of the 160 (12.5%) said they offered it for ongoing treatment.

 

"It's a big issue, but it's something that we can change by supporting these treatment centers with education and technical assistance about buprenorphine, better funding to staff these centers, and by letting the public know that buprenorphine is necessary treatment in healing brains," co-author Dr. Todd Korthuis of Oregon Health & Science University said in a statement.

 


This newsletter was edited by Bill Berkrot.

 

Sponsors are not involved in the creation of newsletters or other Reuters news content.

 

Reuters Health Rounds is sent twice a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.

 

Want to stop receiving this newsletter? Unsubscribe here.
To manage which newsletters you're signed up for, click here.

 
FacebookTwitterInstagram
 

Reuters Terms & Conditions and Privacy Statement

© 2023 Thomson Reuters. All rights reserved.

3 Times Square, New York, NY 10036